Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15%
of all cases diagnosed correspond to the triple negative subtype. Triple negative breast
cancer affects young women with germline mutations in BRCA 1/2 genes. Giving the lack of
target therapies to date, there is no consensus regarding the most effective treatment for
this subgroup of tumors. Although evidence shows that triple negative breast cancer is highly
sensitive to chemotherapy when compared to other breast tumors, there is no evidence to
support the hypothesis that patients with triple negative breast cancer and mutation in BRCA1
/ 2 genes have higher chemosensitivity to neoadjuvant therapy. The investigator proposes a
prospective, randomized, open-label, phase II study, evaluating the rate of complete
pathologic response, disease-free survival, overall survival and prognostic evaluation of
BRCA1 / 2 mutation status in women with triple negative breast cancer submitted to sequential
neoadjuvant chemotherapy based on anthracycline and taxane, with or without carboplatin.